NEW YORK, June 26 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today listed the common stock of Pipex Pharmaceuticals, Inc. under the ticker symbol PP. Pipex Pharmaceuticals, Inc. is a development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. "We are pleased to welcome Pipex Pharmaceuticals to the American Stock Exchange," said John McGonegal, Senior Vice President of the Amex Equities Group. "We look forward to working with an innovative company like Pipex Pharmaceuticals and providing them with the solid support and services that are essential in today's competitive marketplace." "We are very delighted to be listed on the American Stock Exchange," said Steve H. Kanzer, Pipex's co-founder, Chairman and Chief Executive Officer. "We believe this Amex listing will provide our current and future shareholders with a greater degree of visibility and liquidity as Pipex proceeds to an NDA filing and commercialization, for COPREXA for the treatment of neurologic Wilson's disease and our planned randomized, multicenter placebo-controlled trial of COPREXA for idiopathic pulmonary fibrosis (IPF)." The specialist in Pipex Pharmaceuticals, Inc. will be LaBranche & Co., LLC For further information on PP and other Amex-listed companies, please visit http://www.amex.com/. About American Stock Exchange The American Stock Exchange(R) (Amex(R)) offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 324ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com/ About Pipex Pharmaceuticals, Inc. Pipex Pharmaceuticals Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex's strategy is to exclusively in- license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the US and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information please visit http://www.pipexpharma.com/. DATASOURCE: American Stock Exchange CONTACT: Steve H. Kanzer, CPA, Esq., Chairman and Chief Executive Officer of Pipex Pharmaceuticals, Inc., +1-734-332-7800; or Investors, Thomas Redington of Redington, Inc., +1-203-222-7399, http://www.redingtoninc.com/; or Media, Catherine Chantharaj of American Stock Exchange, +1-212-306-1689, Web site: http://www.amex.com/ http://www.pipexpharma.com/

Copyright